Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

2036 - Salivary metabolomics for colorectal cancer detection

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Translational Research

Tumour Site

Presenters

Hiroshi Kuwabara

Citation

Annals of Oncology (2019) 30 (suppl_5): v25-v54. 10.1093/annonc/mdz239

Authors

H. Kuwabara1, A. Iwabuthi2, R. Soya1, M. Enomoto3, T. Ishizaki3, A. Tsuchida1, Y. Nagakawa1, K. Katsumata3, M. Sugimoto4

Author affiliations

  • 1 Department Of Gastrointestinal And Pediatric Surgery, Tokyo Medical University, 160-8402 - Tokyo/JP
  • 2 Center For Health Surveillance And Preventive Medicine, Tokyo Medical University, 160-8402 - Tokyo/JP
  • 3 Department Of Gastrointestinal And Pediatric Surgery, Tokyo Medical University, Tokyo/JP
  • 4 Research And Development Center For Minimally Invasive Therapies Health Promotion And Preemptive Medicine, Tokyo Medical University, Tokyo/JP

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2036

Background

As the worldwide prevalence of colorectal cancer (CRC) is increasing, it is of vital importance to reduce its morbidity and mortality by early detection. Saliva is a noninvasively accessible fluid that potentially reflects both oral and systemic diseases. We report here the investigation and validation of salivary biomarkers to distinguish patients with CRC from those with polyps and healthy controls.

Methods

Saliva samples from subjects with CRC, polyps, and healthy controls were collected after 9 hours of fasting, and were split into training and validation data. Capillary electrophoresis-mass spectrometry-based metabolomics was used to quantify numerous hydrophilic metabolites.

Results

A total of 2,602 unstimulated saliva samples were collected from 231 subjects with CRC, 99 subjects with polyps, and 2272 subjects with healthy controls. The data were randomly divided into training (n = 1,301) and validation data (n = 1301). Biomarkers for distinguishing subjects with CRC from the others, as well as metabolites that normalize whole saliva concentration were identified. Analysis of these metabolites using machine learning-based artificial intelligence showed a high area under the receiver operating characteristic curve (AUC = 0.876; P < 0.0001) in the training dataset. This combination also showed high AUC values using the validation dataset (AUC = 0.861; P < 0.0001). Saliva samples were also collected multiple times from identical subjects and the robustness of these biomarkers were confirmed.

Conclusions

Combinations of salivary metabolites show high potential as a screening tool for CRC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Hiroshi Kuwabara.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.